[Cytokine neutralization at specific cellular source : A new therapeutic paradigm? German Version]

Area of Science:

• Immunology
• Molecular Biology
• Drug Development

Background:

• Current autoimmune disease treatments target general immune control mechanisms, leading to non-curative outcomes and side effects.
• Cytokine manipulation, while common, can disrupt beneficial functions due to the non-redundant roles of specific cytokines.

Purpose of the Study:

• To investigate the distinct roles of tumor necrosis factor (TNF) and interleukin-6 (IL-6) in autoimmune diseases.
• To develop a targeted therapeutic strategy that selectively inhibits pathogenic cytokine functions while preserving beneficial ones.

Main Methods:

• Utilized reverse genetics and conditional gene targeting to study cytokine contributions.
• Designed and tested a myeloid-specific TNF inhibitor (MYSTI), a bispecific mini-antibody targeting F4/80 and TNF.
• Conducted in vitro and in vivo experiments to assess MYSTI's efficacy and safety.

Main Results:

• Identified distinct, non-redundant functions for TNF from different cellular sources.
• Demonstrated that myeloid-derived TNF is pathogenic, while T cell-derived TNF has protective roles in experimental models.
• MYSTI effectively retained TNF on producing cells, protected against TNF-mediated hepatotoxicity, and showed efficacy in experimental arthritis.

Conclusions:

• Selective inhibition of pathogenic cytokine functions presents a more effective therapeutic strategy than broad anti-cytokine approaches.
• Preserving beneficial cytokine effects from other cell types can mitigate side effects.
• Bispecific agents like MYSTI hold promise for both experimental research and future drug development in autoimmune diseases.